This compound, mexiletine hydrochloride, is primarily used in the pharmaceutical industry as an active pharmaceutical ingredient (API) and research reagent for treating ventricular arrhythmias. It functions as a class Ib antiarrhythmic agent by modulating sodium channels in cardiac cells, aiding in the regulation of abnormal heart rhythms associated with cardiovascular conditions. It is not used in the synthesis of beta-blockers but directly contributes to managing arrhythmias. Additionally, it is employed in research for studying cardiac electrophysiology, ion channel interactions, and developing novel antiarrhythmic therapies. Its high purity (97%) ensures reliable results in manufacturing, clinical formulations, and experimental applications.